ناعور مكتسب
مراجع

↑  Hunth-Kühne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Lévesque H, et al. International recommendations on the diagnosis and treatment of pacients with acquired hemophilia A. Haematologica. 2009; 94: 566-75.
↑  Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, et al.Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood 2007;109:1870-7.
↑  Franchini M, Vaglio S, Marano G, Mengoli C, Gentili S, Pupella S, et al. Acquired hemophilia A: a review of recent data and new therapeutic options. Hematology. 2017; 22: 514-20.
↑  Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981;45:200-3.
↑  Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia.Blood 1993;81:1513-20.
↑  Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review. Am J Hematol 2005;80:55-63.
↑  Knoelb P, Marco P, Baudo F, Collins P, Huth-Kuhne A, Nemes L, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012; 10: 622-31.
↑  Bitting RL, Bent S, Li Y, Kohlwes J. The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis. Blood Coagul Fibrinolysis. 2009; 20: 517-23.
↑  Delgado J, Jiménez-Yuste V, Hernández-Navarro F, Villar A. Acquired haemophilia: review and meta analysis focused on therapy and prognostic factors. Br J Haematol. 2003; 121: 21-35.
↑  Pavlova A, Zeitler H, Scharrer I, et al. HLA genotype in patients with acquired haemophilia A. Haemophilia 2010; 16:107.
↑  Wootla B, Desirazu N, Friboulet A, Uda T, Lacroix-Desmazes S, Kaveri S. Varied immune response to FVIII: presence of proteolytic antibodies directed to factor VIII in different human pathologies. Clinic Rev Allerg Immunol. 2009; 37: 97-104.
↑  Mingot-Castellano ME, Núñez R, Rodríguez-Martorell FJ. Acquired haemophilia: Epidemiology, clinical presentation, diagnosis and treatment. Med Clin (Barc). 2017; 148: 314-22.
↑  Nemes L, Tengborn L, Collins PW, Baudo F, Huth-Kuehne A, Knoebl P, et al. Acquired Haemophilia and pregnancy/postpartum- a Report from an European Acquired Registry. Blood. 2010; 116: 717.
↑  Collins P, Baudo F, Huth-Kühne A, Ingerslev J, Kessler CM, Mingot Castellano ME, et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Research Notes. 2010; 3: 161-8.
↑  Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975; 34: 612
↑  Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995; 73: 247-51.
| 0 | 1 |
| --- | --- |
التصنيفات الطبية:  نظام فهرسة المواضيع الطبية (MeSH): C536392  التصنيف الدولي العاشر للأمراض (ICD-10-CM): D68.4  رموز المراجعة العاشرة للتصنيف الدولي للأمراض (ICD-10): D68.4  
المعرفات الخارجية:  مكنز المعهد القومي للسرطان (NCI): C35345  نظام اللغة الطبية الموحدة (UMLS CUI): C0272325  GARD rare disease ID: 10350  
بوابة طب